Loading...

Adam Giermasz

Title(s)Associate Professor, Hematology and Oncology
SchoolUniversity of California, Davis
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Von Drygalski A, Giermasz A, Castaman G, Key NS, Lattimore S, Leebeek FWG, Miesbach W, Recht M, Long A, Gut R, Sawyer EK, Pipe SW. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019 Nov 12; 3(21):3241-3247. PMID: 31698454.
      View in: PubMed
    2. George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017 12 07; 377(23):2215-2227. PMID: 29211678.
      View in: PubMed
    3. Tobase P, Mahajan A, Francis D, Leavitt AD, Giermasz A. A gap in comprehensive care: Sexual health in men with haemophilia. Haemophilia. 2017 07; 23(4):e389-e391. PMID: 28574623.
      View in: PubMed
    4. Escobar MA, Tehranchi R, Karim FA, Caliskan U, Chowdary P, Colberg T, Giangrande P, Giermasz A, Mancuso ME, Serban M, Tsay W, Mahlangu JN. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan; 23(1):67-76. PMID: 27480487.
      View in: PubMed
    5. Kono M, Nakamura Y, Suda T, Uchijima M, Tsujimura K, Nagata T, Giermasz AS, Kalinski P, Nakamura H, Chida K. Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine. Vaccine. 2012 Mar 30; 30(16):2633-9. PMID: 22365841.
      View in: PubMed
    6. Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 2009 Aug; 58(8):1329-36. PMID: 19156413.
      View in: PubMed
    7. Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res. 2007 Oct 15; 67(20):10012-8. PMID: 17942935.
      View in: PubMed
    8. Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res. 2006; 36(1-3):137-46. PMID: 17337774.
      View in: PubMed
    9. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther. 2005 Oct; 5(10):1303-15. PMID: 16197336.
      View in: PubMed
    10. Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol. 2005 Feb; 42(4):535-9. PMID: 15607810.
      View in: PubMed
    11. Stoklosa T, Golab J, Wójcik C, Wlodarski P, Jalili A, Januszko P, Giermasz A, Wilczynski GM, Pleban E, Marczak M, Wilk S, Jakóbisiak M. Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. Apoptosis. 2004 Mar; 9(2):193-204. PMID: 15004516.
      View in: PubMed
    12. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003 Sep 01; 171(5):2366-73. PMID: 12928383.
      View in: PubMed
    13. O'Connell PJ, Son YI, Giermasz A, Wang Z, Logar AJ, Thomson AW, Kalinski P. Type-1 polarized nature of mouse liver CD8alpha- and CD8alpha+ dendritic cells: tissue-dependent differences offset CD8alpha-related dendritic cell heterogeneity. Eur J Immunol. 2003 Jul; 33(7):2007-13. PMID: 12884867.
      View in: PubMed
    14. Jalili A, Stoklosa T, Giermasz A, Olszewska D, Wilczynski G, Jakobisiak M, Golab J. A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index. Oncol Rep. 2002 Sep-Oct; 9(5):991-4. PMID: 12168061.
      View in: PubMed
    15. Dabrowska-Iwanicka A, Olszewska D, Jalili A, Makowski M, Grzela T, Marczak M, Hoser G, Giermasz A, Golab J, Jakóbisiak M. Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice. J Cancer Res Clin Oncol. 2002 Aug; 128(8):433-42. PMID: 12200600.
      View in: PubMed
    16. Feleszko W, Jalili A, Olszewska D, Mlynarczuk I, Grzela T, Giermasz A, Jakóbisiak M. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep. 2002 Jul-Aug; 9(4):879-85. PMID: 12066226.
      View in: PubMed
    17. Kozar K, Kaminski R, Giermasz A, Basak G, Zagozdzon R, Rybczynska J, Wasik M, Lasek W, Jakobisiak M, Golab J. IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells. Oncol Rep. 2002 Mar-Apr; 9(2):427-31. PMID: 11836621.
      View in: PubMed
    18. Giermasz A, Makowski M, Kozlowska E, Nowis D, Maj M, Jalili A, Feleszko W, Wójcik C, Dabrowska A, Jakóbisiak M, Golab J. Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer. 2002 Feb 20; 97(6):746-50. PMID: 11857349.
      View in: PubMed
    19. Giermasz A, Makowski M, Nowis D, Jalili A, Maj M, Dabrowska A, Czajka A, Jakobisiak M, Golab J. Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. Oncol Rep. 2002 Jan-Feb; 9(1):199-203. PMID: 11748483.
      View in: PubMed
    20. Giermasz A, Grzela T, Nowis D, Makowski M, Czajka A, Stoklosa T, Lasek W, Dabrowsk A, Wiznerowicz M, Mackiewicz A, Jakóbisiak M. Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line. Anticancer Res. 2001 Nov-Dec; 21(6A):4001-4. PMID: 11911283.
      View in: PubMed
    21. Gol b J, Zagozdzon R, Kaminski R, Kozar K, Gryska K, Izycki D, Mackiewicz A, Stoklosa T, Giermasz A, Lasek W, Jakóbisiak M. Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia. 2001 Apr; 15(4):613-20. PMID: 11368364.
      View in: PubMed
    22. Giermasz A, Nowis D, Jalili A, Basak G, Marczak M, Makowski M, Czajka A, Mlynarczuk I, Hoser G, Stok osa T, Lewandowski S, Jakóbisiak M. Antitumor activity of tributyrin in murine melanoma model. Cancer Lett. 2001 Mar 26; 164(2):143-8. PMID: 11179828.
      View in: PubMed
    23. Dabrowska A, Giermasz A, Golab J, Jakóbisiak M. Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice. Neoplasma. 2001; 48(5):358-61. PMID: 11845979.
      View in: PubMed
    24. Wójcik C, Bury M, Stoklosa T, Giermasz A, Feleszko W, Mlynarczuk I, Pleban E, Basak G, Omura S, Jakóbisiak M. Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol. 2000 Sep; 32(9):957-65. PMID: 11084375.
      View in: PubMed
    25. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A, Jakóbisiak M. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res. 2000 May; 6(5):2044-52. PMID: 10815931.
      View in: PubMed
    26. Golab J, Wilczynski G, Zagozdzon R, Stoklosa T, Dabrowska A, Rybczynska J, Wasik M, Machaj E, Olda T, Kozar K, Kaminski R, Giermasz A, Czajka A, Lasek W, Feleszko W, Jakóbisiak M. Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. Br J Cancer. 2000 Apr; 82(8):1485-91. PMID: 10780531.
      View in: PubMed
    27. Golab J, Kozar K, Kaminski R, Czajka A, Marczak M, Switaj T, Giermasz A, Stoklosa T, Lasek W, Zagozdzon R, Mucha K, Jakóbisiak M. Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice. Life Sci. 2000 Feb 18; 66(13):1223-30. PMID: 10737417.
      View in: PubMed
    28. Dabrowska A, Giermasz A, Marczak M, Golab J, Jakóbisiak M. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice. Anticancer Res. 2000 Jan-Feb; 20(1A):391-4. PMID: 10769685.
      View in: PubMed
    29. Golab J, Zagozdzon R, Kozar K, Kaminski R, Giermasz A, Stoklosa T, Lasek W, Jakobisiak M. Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo. Oncol Rep. 2000 Jan-Feb; 7(1):177-81. PMID: 10601614.
      View in: PubMed
    30. Zagozdzon R, Giermasz A, Golab J, Stoklosa T, Jalili A, Jakóbisiak M. The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production. Cancer Lett. 1999 Dec 01; 147(1-2):67-75. PMID: 10660091.
      View in: PubMed
    31. Lasek W, Golab J, Maslinski W, Switaj T, Balkowiec EZ, Stoklosa T, Giermasz A, Malejczyk M, Jakóbisiak M. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice. Eur Cytokine Netw. 1999 Sep; 10(3):345-56. PMID: 10477391.
      View in: PubMed
    32. Feleszko W, Balkowiec EZ, Sieberth E, Marczak M, Dabrowska A, Giermasz A, Czajka A, Jakóbisiak M. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer. 1999 May 17; 81(4):560-7. PMID: 10225445.
      View in: PubMed
    33. Dabrowska A, Golab J, Giermasz A, Marczak M, Jakóbisiak M. Re: Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst. 1999 May 05; 91(9):804-6. PMID: 10328115.
      View in: PubMed
    34. Stoklosa T, Wójcik C, Golab J, Giermasz A, Wilk S. Inhibition of proteasome, apoptosis and sensitization to tumour necrosis factor alpha: do they always go together? Br J Cancer. 1999 Jan; 79(2):375-6. PMID: 9888486.
      View in: PubMed
    35. Zagozdzon R, Golab J, Stoklosa T, Giermasz A, Nowicka D, Feleszko W, Lasek W, Jakóbisiak M. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer. 1998 Aug 31; 77(5):720-7. PMID: 9688305.
      View in: PubMed
    36. Golab J, Stoklosa T, Zagozdzon R, Kaca A, Kulchitska LA, Feleszko W, Kawiak J, Hoser G, Glowacka E, Dabrowska A, Giermasz A, Lasek W, Jakóbisiak M. Granulocyte-macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice. Tumour Biol. 1998; 19(2):77-87. PMID: 9486559.
      View in: PubMed
    37. Golab J, Stoklosa T, Zagozdzon R, Kaca A, Giermasz A, Pojda Z, Machaj E, Dabrowska A, Feleszko W, Lasek W, Iwan-Osiecka A, Jakóbisiak M. G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann Oncol. 1998 Jan; 9(1):63-9. PMID: 9541685.
      View in: PubMed
    38. Golab J, Zagozdzon R, Stoklosa T, Kaca A, Dabrowska A, Giermasz A, Feleszko W, Jakóbisiak M. Granulocyte colony-stimulating factor demonstrates antitumor activity in melanoma model in mice. Neoplasma. 1998; 45(1):35-9. PMID: 9605000.
      View in: PubMed
    39. Zagozdzon R, Stoklosa T, Golab J, Giermasz A, Dabrowska A, Lasek W, Jakóbisiak M. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model. Anticancer Res. 1997 Nov-Dec; 17(6D):4493-8. PMID: 9494557.
      View in: PubMed
    40. Wójcik C, Stoklosa T, Giermasz A, Golab J, Zagozdzon R, Kawiak J, Wilk S, Komar A, Kaca A, Malejczyk J, Jakóbisiak M. Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. Apoptosis. 1997; 2(5):455-62. PMID: 14646528.
      View in: PubMed
    41. Lasek W, Giermasz A, Kuc K, Wankowicz A, Feleszko W, Golab J, Zagozdzon R, Stoklosa T, Jakóbisiak M. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Int J Cancer. 1996 May 03; 66(3):374-9. PMID: 8621260.
      View in: PubMed
    42. Feleszko W, Giermasz A, Golatb J, Lasek W, Kuc K, Szperl M, Jakóbisiak M. Granulocyte-macrophage colony-stimulating factor accelerates growth of Lewis lung carcinoma in mice. Cancer Lett. 1996 Mar 29; 101(2):193-7. PMID: 8620469.
      View in: PubMed
    43. Lasek W, Wankowicz A, Kuc K, Feleszko W, Giermasz A, Jakóbisiak M. Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice. Oncology. 1996 Jan-Feb; 53(1):31-7. PMID: 8570128.
      View in: PubMed
    44. Lasek W, Wankowicz A, Kuc K, Feleszko W, Golab J, Giermasz A, Wiktor-Jedrzejczak W, Jakóbisiak M. Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. Cancer Immunol Immunother. 1995 May; 40(5):315-21. PMID: 7600564.
      View in: PubMed